| Name | CRA-026440 |
| Description | CRA-026440(PCI-34051) is a highly potent HDAC inhibitor with inhibitory effects on HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 and HDAC10 with Ki values of 4,14,11,15,7 and 20 nM, respectively. CRA-026440 has anti-tumor and anti-angiogenic activity and can be used to study colon cancer. |
| In vitro | CRA-026440 exhibits anti-proliferative effects on HUVEC endothelial cells with a GI50 value of 1.41 μM[1].
In tumor cells, treatment with CRA-026440 (0.1-10 μM; 18 hours) leads to the accumulation of acetylated histones and acetylated microtubule proteins, thereby inhibiting tumor cell growth and inducing apoptosis[1].
CRA-026440 (0.1-10 μM; 5 days) inhibits ex vivo angiogenesis in a dose-dependent manner[1]. |
| In vivo | Administered intravenously at a dose of 100 mg/kg daily for three consecutive days, CRA-026440 significantly reduces tumor growth in mice bearing HCT116 or U937 human tumor xenografts[1]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90 mg/mL (214.05 mM), Sonication is recommended.
|
| Keywords | HDAC8 | HDAC6 | HDAC3 | HDAC2 | HDAC10 | HDAC1 | HDAC | CRA-026440 | CRA026440 | CRA 026440 |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | Tributyrin | L-Methionine | Sodium citrate | Cystamine dihydrochloride | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
United States
